Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CABA

Cabaletta Bio Inc

Nov 14 • 04:00PM ET

2.31

-0.03 -1.28 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE BMRN EDIT TGTX NTLA ALLO SGMO ANIX ADAP

| Held by: VTI VXF IWC PRFZ AVSC TMED MSSM BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	13.61%	Shs Outstand	96.27M	Perf Week	-9.41%
Market Cap	222.37M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.00%	Shs Float	84.34M	Perf Month	-19.79%
Enterprise Value	88.22M	PEG	-	EPS next Q	-0.47	Inst Own	73.26%	Short Float	15.35%	Perf Quarter	30.51%
Income	-158.52M	P/S	-	EPS this Y	4.40%	Inst Trans	12.92%	Short Ratio	3.41	Perf Half Y	13.79%
Sales	0.00M	P/B	1.59	EPS next Y	20.10%	ROA	-80.43%	Short Interest	12.95M	Perf YTD	1.76%
Book/sh	1.45	P/C	1.39	EPS next 5Y	9.43%	ROE	-101.06%	52W High	5.46 -57.69%	Perf Year	-46.28%
Cash/sh	1.66	P/FCF	-	EPS past 3/5Y	-9.16% -20.35%	ROIC	-110.07%	52W Low	0.99 134.35%	Perf 3Y	19.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.36% 11.95%	Perf 5Y	-82.34%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-17.21%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.72	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	3.60	EPS Q/Q	29.14%	SMA20	-11.75%	Beta	3.21	Target Price	14.12
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	-4.91%	Rel Volume	0.67	Prev Close	2.34
Employees	161	LT Debt/Eq	0.03	Earnings	Nov 10 BMO	SMA200	23.39%	Avg Volume	3.80M	Price	2.31
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.72% -	Trades		Volume	2,532,935	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-25	Resumed	Jefferies	Buy	$14
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$15 → $6
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12 → $6
Oct-10-24	Initiated	UBS	Buy	$10
Feb-05-24	Initiated	Jefferies	Buy	$36
Nov-29-23	Initiated	William Blair	Outperform	$38
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-19-23	Initiated	Stifel	Buy	$31
Sep-05-23	Initiated	Citigroup	Buy	$22
Jul-18-23	Initiated	Guggenheim	Buy	$34
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$3 → $16
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $3
Dec-08-21	Initiated	Wells Fargo	Overweight	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$20
Jun-30-21	Initiated	Mizuho	Buy	$22
Jan-08-21	Initiated	Chardan Capital Markets	Buy	$21
Oct-13-20	Initiated	H.C. Wainwright	Buy	$20
Nov-19-19	Initiated	Morgan Stanley	Overweight	$19
Nov-19-19	Initiated	Evercore ISI	Outperform	$25
Nov-19-19	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-10-25 07:30AM	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks) -10.30%
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December (GlobeNewswire)
Oct-31-25 05:42AM	Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials (Insider Monkey) +46.15%
Oct-27-25 07:00AM	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 (GlobeNewswire) +12.96%
08:00AM	Loading…
Oct-14-25 08:00AM	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant (GlobeNewswire) +16.06%
Oct-09-25 12:00PM	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress (GlobeNewswire) +18.26%
Aug-27-25 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-11-25 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's Why (Zacks)
Aug-07-25 07:30AM	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 09:54AM	Cabaletta Bio Announces Pricing of Public Offering of Securities (GlobeNewswire) -25.53%
06:15AM	Cabaletta Bio Announces Proposed Public Offering of Securities (GlobeNewswire)
06:00AM	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress (GlobeNewswire)
May-29-25 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
07:00AM	Loading…
May-15-25 07:00AM	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts (GlobeNewswire) +39.23%
Apr-01-25 12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks) -15.52%
Mar-31-25 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.65%
Mar-19-25 07:00AM	Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform (Business Wire) +6.59%
Feb-26-25 08:00AM	Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 10:21AM	UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire) -14.02%
07:00AM	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire)
Feb-11-25 08:00AM	Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February (GlobeNewswire)
Jan-29-25 08:00AM	Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 (GlobeNewswire)
Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
04:30PM	Loading…
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)
Aug-23-23 08:50AM	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why (Zacks)
Aug-22-23 08:00AM	Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 (GlobeNewswire)
Aug-15-23 01:46PM	Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect? (Zacks)
Aug-10-23 07:00AM	Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia) -7.27%
Jul-24-23 08:00AM	Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors (GlobeNewswire) -6.68%
Jul-18-23 02:58PM	Why Shares of Cabaletta Bio Are Up Tuesday (Motley Fool) +11.93%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire) -5.26%
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
May-31-23 08:00AM	Cabaletta Bio to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:33AM	Institutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growth (Simply Wall St.)
May-22-23 04:30PM	Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
May-17-23 10:16PM	Cabaletta Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.83%
04:01PM	Cabaletta Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-16-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis (GlobeNewswire) +14.63%
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia) +6.67%
07:00AM	Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 04:35PM	Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +5.70%
May-01-23 07:00AM	Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 (GlobeNewswire) +9.83%
Apr-25-23 01:07PM	Great news for Cabaletta Bio, Inc. (NASDAQ:CABA): Insiders acquired stock in large numbers last year (Simply Wall St.) -5.94%
08:00AM	Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-13-23 04:30PM	Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus (GlobeNewswire) +16.48%
Mar-16-23 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:14AM	We're Keeping An Eye On Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate (Simply Wall St.) +8.02%
Feb-28-23 08:00AM	Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-19-23 10:53AM	TipRanks Perfect 10 List: Theres an Opportunity Brewing in These 2 Stocks (TipRanks)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CABA

Cabaletta Bio Inc

Upgrade your FINVIZ experience